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Background. The (H1N1)pdm09 live attenuated influenza vaccine (LAIV) strain was changed for the 2017–2018 influenza 
season to improve viral fitness, following poor protection against (H1N1)pdm09 viruses in 2015–2016. We conducted LAIV virus 
shedding studies to assess the effect of this change.
Methods. Children aged 2–18 years were recruited to receive LAIV in the 2016–2017 (n = 641) and 2017–2018 (n = 362) influenza 
seasons. Viruses from nasal swabs taken 1, 3, and 6 days postvaccination were quantified by reverse-transcription polymerase chain re-
action and area under the curve titers were determined. Presence and quantity of shedding were compared between strains and seasons 
with adjustment for age and prior LAIV (n = 436), inactivated seasonal vaccine (n = 100), or (H1N1)pdm09 vaccine (n = 166) receipt.
Results. (H1N1)pdm09 detection (positivity) in 2016–2017 and 2017–2018 (11.2% and 3.9%, respectively) was lower than that 
of H3N2 (19.7% and 18.7%, respectively) and B/Victoria (28.9% and 33.9%, respectively). (H1N1)pdm09 positivity was higher in 
2016–2017 than 2017–2018 (P = .005), but within shedding-positive participants, the (H1N1)pdm09 titer increased in 2017–2018 
(P = .02). H3N2 and influenza B titers were similar between seasons. Positivity declined with age, and prior vaccination reduced the 
likelihood of shedding influenza B but not (H1N1)pdm09.
Conclusions. The (H1N1)pdm09 titer increased in 2017–2018, indicating more efficient virus replication in shedding-positive 
children than the 2016–2017 strain, although overall positivity was reduced. Age and vaccination history require consideration when 
correlating virus shedding and protection.
clinical Trials Registration. NCT02143882, NCT02866942, and NCT03104790.
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An intranasally administered live attenuated influenza vaccine 
(LAIV; FluMist/Fluenz; AstraZeneca/MedImmune) was licensed 
in 2003 in the United States (US), where annual vaccination of 
6-month-olds to 18-year-olds has been recommended since 2008 
[1]. LAIV has been preferentially recommended for pediatric vac-
cination in some countries, including the United Kingdom (UK), 
as it provides ease of administration and likely more durable and 
broader protection than inactivated influenza vaccines (IIVs) [2]. 
However the subsequent performance of LAIV in the field has 
been variable globally. In the 2013–2014 influenza season, vac-
cine effectiveness (VE) in the US was significantly lower for LAIV 
than IIV, particularly against (H1N1)pdm09 viruses [3, 4]. For 
the 2015–2016 influenza season, the A/California/07/09(H1N1) 
pdm09-like strain was replaced with A/Bolivia/559/2013-like 
virus in a quadrivalent formulation including both B/Victoria (B/
Vic)– and B/Yamagata (B/Yam)–lineage viruses [2]. However, no 
statistically significant VE against (H1N1)pdm09 was observed 
by the US Centers for Disease Control and Prevention in 2015–
2016 [5, 6]. The Advisory Committee on Immunization Practices 
subsequently recommended temporary suspension of LAIV use 
in 2016–2017 in the US [7].
LAIV has been licensed for pediatric vaccination in Europe 
since 2010 and was first included in the UK vaccine schedule in 
2013 as the vaccine of choice for 2- to 16-year-olds [2]; however, 
IIV continues to be recommended for high-risk children aged 
6–24 months for whom LAIV is not licensed [8]. In contrast to 
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2015–2016 demonstrated (H1N1)pdm09 VE estimates compa-
rable to previous seasons and markedly higher than that observed 
in the US [8–11]. Several potential causes have been postulated to 
explain the low (H1N1)pdm09 VE estimates observed in the US, 
including vaccine–virus interference, prior vaccination, replica-
tive fitness of (H1N1)pdm09, or biases arising from differences in 
design between the various observational studies [11–13]. As low 
VE was observed with both trivalent [14–16] and quadrivalent 
LAIV [5, 6] virus interference specific to the quadrivalent formu-
lation is considered less likely [17]. However, viral replicative fit-
ness is a potential factor as both the recently mammalian adapted 
A/California/07/09(H1N1)pdm09-like and A/Bolivia/559/2013-
like strains have shown reduced replication in human alveolar and 
primary nasal epithelial cells, compared to previous H1N1 strains 
that have shown high effectiveness in children [12]. Consequently 
for the 2017–2018 vaccine, the A/Bolivia/559/2013-like virus was 
replaced with A/Slovenia/2903/15-like virus, shown to have in-
creased replicative ability and higher seroconversion rates in chil-
dren aged 2 to <4 years [18, 19].
Although LAIV was not recommended for use in the US in 
2016–2017 [7, 18], it was used in Europe, including the UK, and 
Canada [2, 20]. The UK Joint Committee on Vaccination and 
Immunisation (JCVI) reviewed UK data and recommended 
continued LAIV use in 2016–2017, with close monitoring of 
performance [2]. In the UK, the overall VE of LAIV against 
all subtypes in 2016–2017 was 65.8% (95% confidence interval 
[CI], 30.3%–83.2%) (Supplementary Table 1), in a season dom-
inated by H3N2 and influenza B; however, due to lack of circu-
lation, estimating (H1N1)pdm09-specific VE was not possible 
[21]. Although in the UK the overall VE of LAIV against all sub-
types in 2017–2018 was only 26.9% (95% CI, −32.6% to 59.7%), 
(H1N1)pdm09-specific VE was 90.3% (95% CI, 16.4%–98.9%), 
suggesting that the (H1N1)pdm09 strain change may have im-
proved replicative fitness [22]. The strain change provided an 
opportunity to test the hypothesis that reduced viral fitness of 
the (H1N1)pdm09 vaccine strain may have contributed to low 
VE in 2015–2016. This study was designed to quantify levels 
of all 4 LAIV viruses shed postvaccination from UK pediatric 
LAIV recipients with varying vaccination histories from co-
horts recruited in 2016–2017 and 2017–2018, to determine 
whether a difference could be observed in viral replication and 
subsequent immune protection after the (H1N1)pdm09 strain 
change and to explore the contribution of age and prior vacci-
nation to viral shedding.
MATERIALS AND METHODS
Study Approval
This study was approved by the UK Medicines and Healthcare 
Products Regulatory Agency (EudraCT numbers 2013-003592-
35, 2016-002352‐24, and 2017-000952-24) and the National 
Health Service (NHS) Human Research Authority (HRA) (ap-
proval numbers 14/LO/0227, 16/WM/0276, and 17/LO/0719) 
and registered prospectively with ClinicalTrials.gov (identifiers 
NCT02143882, NCT02866942, and NCT03104790).
Study Design
This study was designed (1) to determine, in children with the 
same vaccination history, effects of the 2017–2018 (H1N1)
pdm09 vaccine strain change on viral shedding and (2) to de-
termine any association between virus shedding and prior 
vaccine status. This analysis utilized samples from 3 open-
label, nonrandomized phase 4 studies over the 2016–2017 and 
2017–2018 influenza seasons, to quantify viral shedding from 
LAIV recipients. Participants received LAIV according to the 
summary of product characteristics (SmPC) in line with UK 
Department of Health guidance. Nasal swabs were taken as 
described below.
Samples were included from 2 cohorts who received LAIV 
in 2016–2017 and 2017–2018. Vaccine-naive and twice LAIV-
vaccinated children between the ages of 6 and <14  years at 
enrollment were recruited from year 3 of a longitudinal study 
(LAIV-Immuno; EudraCT 2013-003592-35; HRA approval 
number 14/LO/0227) to document serological responses to 
annual LAIV vaccination [23]. Inclusion/exclusion criteria 
were as per the approved SmPC. Recruitment was boosted 
with participants from a prospective, multicenter UK trial as-
sessing LAIV safety in children with asthma (the “Safety of 
nasal influenza immunisation in children with asthma” study; 
SNIFFLE-4; EudraCT 2016-002352‐24; HRA approval number 
16/WM/0276), resulting in opportunistic recruitment of parti-
cipants aged 2–18 years. Inclusion criteria required a physician 
diagnosis of asthma or recurrent wheezing, with exclusion cri-
teria (with the exception of severe asthma) as per the SmPC and 
Public Health England guidance [24]. A third cohort was estab-
lished for 2017–2018 (Flu-Shed study; EudraCT 2017-000952-
24; HRA approval number 17/LO/0719; ClinicalTrials.gov 
identifier NCT02866942), in which children aged 6 to <14 years 
at enrollment with either LAIV vaccination in at least 2 of the 3 
previous years or who had never received any influenza vaccine 
were recruited in 3 sites (Hertfordshire and Gloucestershire 
primary care sites; Imperial College Healthcare NHS Trust, 
London). Participant vaccination history was determined by 
reference to medical records and parental questionnaire. For all 
studies, written informed consent was given by parent/guardian 
as well as assent from the child. Vaccination was deferred if a 
participant had a fever ≥38°C on the appointment day or recent 
wheezing. Participating families were asked to report any ad-
verse events requiring medical attention.
Vaccine
LAIV (Fluenz Tetra, AstraZeneca UK Ltd) was administered 
according to the approved SmPC. The 2016–2017 vaccine 
contained A/Bolivia/559/2013(H1N1)pdm09-like, A/New 
Caledonia/71/2014(H3N2)-like, B/Phuket/3073/2013-like (B/
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2017–2018 vaccine, A/Bolivia/559/2013(H1N1)pdm09-like 
virus was replaced with A/Slovenia/2903/2015(H1N1)pdm09-
like virus.
Sample Collection and Processing
Day of vaccination was day 0. Nasal swabs taken on days 1, 3, 
and 6 postvaccination were placed in 2 mL of viral transport 
media and either posted the same day or stored at 4°C until the 
next available post. Upon receipt, reverse-transcription quan-
titative polymerase chain reaction (RT-qPCR) samples were 
prepared by adding 150 µL of sample to 50 µL of lysis buffer 
(MagNa Pure LC Total Nucleic Acid Isolation Kit, Roche) con-
taining internal control RNA (soil-borne cereal mosaic viral 
RNA) and stored at −80°C prior to testing.
Blood samples were taken prevaccination and 21 days later 
(window of 21–42 days). Samples were analyzed for serum an-
tibody titers against the 4 LAIV strains by hemagglutination 
inhibition and neuraminidase inhibition enzyme-linked lectin 
assays as previously described [23].
Nucleic Acid Extraction and RT-qPCR
Viral RNA was extracted from samples, standards, and controls 
using a MagNAPure nucleic acid isolation system (Roche). Two 
quantitative multiplex 1-step RT-qPCR assays were developed 
to amplify specific regions of the hemagglutinin gene of all 4 
LAIV viruses and the internal control RNA. A triplex assay was 
designed to amplify (H1N1)pdm09, H3N2, and B/Vic-lineage 
RNA, with the B/Yam-lineage and internal control RNA amp-
lified in a duplex assay. RT-qPCR reactions were performed 
using TaqPath 1-Step Multiplex Mastermix (without ROX, 
with MUSTANG PURPLE) according to the manufacturer’s 
instructions and gene-specific primers/probes (Supplementary 
Table 2). Amplification and analysis were performed on a 
QuantStudio 7-Flex platform (Applied Biosystems).
The RT-qPCR limit of detection (LOD) corresponding to 95% 
positivity was determined for all strains by probit analysis. Test 
sample viral quantities were determined from standard curves of 
plaque-forming units (PFU) vs cycle threshold value generated 
from serial 10-fold dilutions of the 4 viruses at known titers, in 
quadruplicate on each PCR plate. Samples were analyzed in du-
plicate and mean PFU values determined. If a mean PFU value 
fell below the LOD, the sample was reanalyzed for all 4 viruses. 
PFU values above the LOD were converted to PFU/mL titers.
Statistical Analyses
PFU results were log-transformed, and the area under the 
curve (AUC) was calculated and divided by 6 to obtain an av-
erage per day, antilogged, and multiplied by 133.33 to obtain 
PFU/mL/day. For day 6 swabs taken on day 5 or days 7–10, the 
day 6 value was estimated by linear interpolation. AUC was 
expressed as the geometric mean with 95% CI. Effects of age, 
season, and prior vaccination on shedding rates were assessed 
by multiple logistic regression. Linear regression on logged 
AUC was used to obtain age and fold differences between years 
after adjusting for age and vaccine history. AUC was com-
pared using the nonparametric Kruskal-Wallis test. For season 
comparisons, results from 2- to 6-year-olds in both seasons 
were excluded due to insufficient numbers in this age group 
in 2017–2018. Shedding between strains within each year was 
compared using McNemar exact test. The target sample size 
for 2017–2018 was 400 which, when compared with the known 
sample size of >400 for 2016–2017, allowed differences in shed-
ding rates of 10% to be detectable at 80% power and 5% signif-
icance. Serum antibody geometric mean titers were calculated 
with 95% CI and compared by normal-error regression. The 
proportion of samples displaying a minimum 4-fold increase 
in neutralizing antibody levels pre- to postvaccination (sero-
conversion) were compared by Fisher exact test. Significance 
was taken at 5% except for comparison of shedding rates be-




Six hundred forty-one and 362 participants were recruited and 
vaccinated during the 2016–2017 and/or 2017–2018 influenza 
seasons, respectively; of these, 436 and 310, respectively, pro-
vided all 3 nasal swabs (Figure 1). At least 1 swab was provided 
by 531 participants in 2016–2017 (with 116 also providing 
paired pre- and postvaccination blood samples) and 354 in 
2017–2018. Characteristics of the 2 cohorts were broadly sim-
ilar, with some differences in age distribution (Supplementary 
Table 3) and prior LAIV receipt, reflecting the opportunistic re-
cruitment of the 2016–2017 participants (Table 1). Recipients 
of prior trivalent inactivated influenza vaccine (TIV) were pre-
dominantly SNIFFLE-4 recruits in 2016–2017. The proportion 
having received the AS03 adjuvanted (H1N1)pdm09 vaccine 
(Pandemrix) in 2009–2010 was similar in both cohorts.
Quantitation of Viral Shedding
Samples from participants that provided 3 swabs were analyzed 
by RT-qPCR. (H1N1)pdm09 virus (H1) positivity was signif-
icantly lower than all other strains (P < .001) in both seasons. 
H1 virus shedding was detected in 11.2% of individuals in 
2016–2017, which declined to 3.9% in 2017–2018 (P = .005). In 
both seasons, H3N2 virus (H3) positivity was similar (19.7% 
and 18.7% in 2016–2017 and 2017–2018, respectively), but 
significantly lower than the influenza B viruses (P <  .001). B/
Vic-lineage and B/Yam-lineage viruses were present in 27.5%–
33.9% of samples (Table 2). Although positivity was higher for 
B/Vic than B/Yam, this was not significant (P = .49).
In individuals with detectable virus shedding, the H1 av-
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2016–2017, but increased in 2017–2018 (362 PFU/mL/day) to 
titers similar to the influenza B viruses (Table 2). Nearly 80% of 
H1-positive 2016–2017 samples contained the lowest detectable 
titers (133 PFU/mL/day), with only 4% of samples showing a 
>2-fold increase (Figure 2A). However, in 2017–2018, only 50% 
of H1-positive samples contained the lowest detectable titers, 
with 33% of samples containing at least a 4-fold increase in titer. 
The majority of H3-positive samples contained titers at either 
the lowest detectable level or 2-fold higher (Figure 2B); however, 
unlike H1 this was observed in both seasons (89% and 94% of 
samples in 2016–2017 and 2017–2018, respectively). Influenza 
B virus titers were similar in both seasons and demonstrated a 
wider distribution, with B/Vic having the highest titers (up to 
6 × 104 PFU/mL/day) (Figure 2C and 2D).




Sex, male/total 241/436 (55) 144/310 (46)
Age group, y   
 2–6 93 (21) 8 (3)
 7–11 225 (52) 205 (66)
 12–18 118 (27) 97 (31)
LAIV received in previous season, yes/total 307/430 (71) 129/310 (42)
Previous TIV vaccination, yes/total 96/432 (22) 4/310 (1)
Previous vaccination with Pandemrix, yes/total 101/387 (26) 65/271 (24)
Any past influenza vaccination recorded, yes/total 342/432 (79) 154/310 (50)
Data are presented as N (%) and n/N (%).
Abbreviations: LAIV, live attenuated influenza vaccine; TIV, trivalent inactivated influenza 
vaccine.
Figure 1. Study flowchart. Children aged 2–18 years, either influenza vaccine naive or with live attenuated influenza vaccination in at least 2 of the 3 previous years, were 
recruited during the 2016–2017 and 2017–2018 influenza seasons. Samples from participants from whom 3 swabs were received (taken on days 1, 3, and 6 postvaccination) 
were subjected to quantitative viral shedding analysis. Blood samples were only taken during the 2016–2017 season and used to determine serum antibody titers pre- and 
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Table 2. Live Attenuated Influenza Vaccine Virus Shedding and Comparison Between Influenza Seasons
Measure 
 Influenza Subtype
Influenza Season aOR or Fold Difference (2017–2018 vs 2016–2017)
P Valuea2016–2017 2017–2018 (95% CI)b
Positivity H1 11.2% (49/436) 3.9% (12/310) 0.34 (.16–.73) .005 
% of total samples (no./No.)c H3 19.7% (86/436) 18.7% (58/310) 1.18 (.75–1.85) .48
B/Victoria 28.9% (126/436) 33.9% (105/310) 1.54 (1.05–2.26) .03 
 B/Yamagata 27.5% (120/436) 28.4% (88/310) 1.21 (.83–1.77) .33
Geometric mean AUC (95% CI) H1 204 (181–231) 362 (206–638) 1.52 (1.08–2.13) .02
PFU/mL/d (95% CI)d 
 
H3 263 (222–312) 224 (189–267) 0.90 (.73–1.12) .83
B/Victoria 719 (547–945) 466 (368–590) 1.12 (.79–1.57) .47
 B/Yamagata 417 (340–513) 275 (230–329) 0.87 (.67–1.14) .11
Abbreviations: aOR, adjusted odds ratio; AUC, area under the curve; CI, confidence interval; PFU, plaque-forming units.
aSignificant results (P < .05) are in bold.
bNot including data from the age group 2–6 years due to low sample numbers.
cAdjusted odds ratio within those positive adjusted for age and any prior influenza vaccination.
dFold difference in PFU/mL within those positive, adjusted for age and any prior influenza vaccination.
Figure 2. Analysis of viral shedding titers. The area under the curve titers (PFU/mL/day) of individual virus-positive samples were separated into 9 groups, ranging from the 
lowest (133 PFU/mL) to the highest observed titer for any subtype, on a 2-fold increasing scale. The percentage of samples in each group is shown as samples positive for H1 
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Adjusted odds ratio (aOR) analysis of virus positivity for 
2017–2018 compared to 2016–2017 samples gave a statisti-
cally significant aOR of 0.34 for H1 (95% CI, .16–.73), showing 
that the H1 virus was less likely to shed in 2017–2018 than in 
2016–2017 (Table 2). The aOR for H3 and B/Yam included 1.0, 
suggesting that these viruses were just as likely to shed in both 
seasons, whereas for B/Vic the aOR was >1.0, indicating higher 
shedding in 2017–2018 (Table 2). However, when comparing 
shedding titers between the 2 seasons, the AUC fold difference 
for H1 (1.52) was statistically significant, indicating that indi-
viduals who shed H1 were more likely to shed higher titers in 
2017–2018 than in 2016–2017. The AUC fold difference for H3, 
B/Vic, and B/Yam ranged from 0.87 to 1.12, with none signifi-
cant, suggesting little difference in the quantity of shedding be-
tween seasons.
Effects of Age and Vaccination History on Shedding
Age-stratified results (2–6, 7–11, and 12–18  years) showed 
that for all viruses, the proportion of virus-positive samples 
decreased with increasing age in 2016–2017 (Figure 3 and 
Supplementary Table 4). With the exception of B/Yam, the same 
was observed in 2017–2018. This was confirmed by logistic re-
gression analysis where adjustment was made for any prior vac-
cination (Table 3).
LAIV receipt in the previous season had no effect on shed-
ding of H1 or H3 in either season but significantly reduced 
shedding of both influenza B viruses in 2016–2017 and B/Vic 
in 2017–2018 (aOR <1) (Table 3 and Supplementary Table 5).
There was no significant effect of TIV or Pandemrix receipt on 
any virus in either season. Results for any previous influenza 
vaccination were similar to those when assessing LAIV receipt 
in the previous season.
Serological Responses to Vaccination
In the 2016–2017 cohort, prevaccination geometric mean titers 
were similar between shedding-positive and -negative individ-
uals, with the exception of B/Vic, where they were significantly 
lower in shedding-positive individuals (47.1 vs 88.6). Few indi-
viduals seroconverted, and although seroconversion rates were 
slightly higher in shedding-positive individuals, results were 
not significant (Table 4).
DISCUSSION
By comparing levels of the 4 viruses shed from pediatric LAIV 
recipients in the 2016–2017 and 2017–2018 seasons in the UK, 
we sought to determine if increased viral replication/shedding 
was observed in the clinical setting after the change in (H1N1)
pdm09 (H1) strain for the 2017–2018 season. Sample positivity 
and virus shedding titers for H3, B/Vic, and B/Yam viruses were 
similar between seasons (Table 2 and Figure 2), likely due to the 
lack of strain changes and both cohorts containing individuals 
with varying vaccination histories. The 2016–2017 H1 virus, A/
Bolivia/559/2013(H1N1)pdm09-like, was shed in fewer parti-
cipants and at a significantly lower titer than the other 3 vir-
uses. Although higher shedding positivity of the 2017–2018 
H1 virus, A/Slovenia/2903/2015(H1N1)pdm09-like, was previ-
ously shown [19], the current study demonstrated H1 shedding 
from significantly fewer participants in 2017–2018 compared 
Figure 3. The effect of participant age on viral shedding. The figure shows the percentage of total samples analyzed that were positive for each subtype when stratified 
by age in the 2016–2017 and 2017–2018 cohorts.
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with 2016–2017 (Table 2). However the study design differed 
between these 2 studies, which must be taken into consider-
ation when comparing results. The previous study [19] was 
designed to minimize the impact from prior infection or vac-
cination, whereas the current study aimed to assess shedding in 
both vaccine-naive and twice LAIV-vaccinated individuals to 
address the effect of prior vaccination on LAIV virus shedding. 
Furthermore, the previous study was performed in the summer 
months, whereas the current study was performed during the 
influenza season and reflected the real-world use of LAIV in 
the UK. As a result, the cohorts in the 2 studies differed in par-
ticipant age, vaccination history, and serostatus, all of which are 
likely to impact virus shedding. This illustrates the complexity 
of studying vaccine responses in different cohorts, as even sim-
ilar cohorts vaccinated with the same vaccine but in different 
countries have demonstrated significantly different VE results 
[16, 25]. Nevertheless, results of the current study demonstrated 
that in those individuals who did shed H1, the average titer was 
higher than the previous year, consistent with the findings that 
the 2017–2018 strain change increased H1 replication [19]. 
However, the significantly lower shedding positivity in 2017–
2018 warrants further investigation regarding the implications 
for VE.
A significant negative association between participant age and 
shedding was observed (Table 3). Younger individuals are less 
likely to have undergone repeated influenza exposure through 
vaccination or infection, and therefore less likely to have pre-
existing immunity. This would be consistent with higher LAIV 
VE observed in children compared to 18- to 49-year-olds [26]. 
However, the negative association between shedding and age 
was independent of vaccination history (Table 3) and for 3 of 
the viruses, no association between prevaccination antibody 
titers and shedding was observed (Table 4). The factors respon-
sible for the age effect are therefore unclear and require further 
investigation.
Prior vaccination was associated with reduced shedding, at 
least for influenza B viruses, independently of age. This was 
not the case for (H1N1)pdm09. If the effect of prior LAIV on 
shedding is mediated by preexisting immunity, it may depend 
on cell-mediated or mucosal antibody responses, factors not 
measured in our study, as there was no relationship between 
prevaccination titers and shedding. Furthermore, prior receipt 
of TIV or Pandemrix, a monovalent ASO3-adjuvanted vaccine 
associated with elevated neutralizing antibody levels to (H1N1)
pdm09 [23], also had no effect on shedding. Preexisting cellular 
immunity has been shown to negatively correlate with LAIV-
induced T-cell responses in children but not adults [27].
The minimal seroconversion observed, regardless of shedding 
status, demonstrates that vaccine virus shedding levels and LAIV-
mediated serum antibody responses do not correlate with the high 
(H1N1)pdm09 VE observed in the UK during the 2017–2018 
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seroconversion rates are known to be poor correlates of protection 
in LAIV-vaccinated children [17], and a lack of correlation be-
tween mucosal antibody, cytokine or chemokine levels, and pro-
tection has previously been noted [28]. Results of this study suggest 
that attempting to correlate quantitative virus shedding with clin-
ical protection may be a complex process requiring consideration 
of multiple factors, such as recipient age and vaccination history. 
In future studies, if virus shedding is to be investigated as an indi-
cator of LAIV viral strain replicative fitness and a potential corre-
late of protection, the focus should be on LAIV-naive children aged 
2–6 years, in whom shedding rates are highest.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases on-
line. Consisting of data provided by the authors to benefit the reader, the 
posted materials are not copyedited and are the sole responsibility of the 
authors, so questions or comments should be addressed to the corre-
sponding author.
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